Acquisition expansion LICORbio recently expanded through the acquisition of SERVA Electrophoresis, signaling growth in electrophoresis reagents, consumables, and workflow instrumentation. This presents cross-selling opportunities for imaging solutions paired with SERVA’s electrophoresis portfolio and potential integration into combined workflows.

Imaging leadership With a strong position in life science imaging and analytical solutions and substantial peer-reviewed citations, LICORbio can be positioned as a premium partner for labs needing reliable, quantitative imaging. Sales efforts can highlight compatibility with existing electrophoresis workflows and software ecosystems.

Financial scale Revenue in the range of 100 to 250 million indicates a mid-market company with budgeting authority for asset-level upgrades. Target procurement stakeholders responsible for lab automation, software, and reagent supply chains in mid-to-large research operations.

Strategic partnerships LICORbio’s tech stack highlights integration capabilities across software, cloud, and automation tools. This opens door to partnerships with labs seeking end-to-end imaging workflows, data management, and scalable support across platforms.

Global workflow The acquisition of Serva Electrophoresis brings geographic and product diversification (Germany and broader Europe). This suggests opportunities to expand into new regional markets with bundled imaging and electrophoresis solutions, as well as localized support and training offerings.